Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.57 |
| ▸ | ACACA | Q13085 | 3/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619607 | 0.82 | ACACB (0.57) | ACACBACACAMMP12FFAR1FFAR4 | |
| SCHEMBL7615628 | 0.80 | ACACB (0.54) | ACACBACACAMMP12FFAR1FFAR4 | |
| SCHEMBL12783525 | 0.78 | ENPP2 (0.53) | ACACBFFAR1FFAR4MAOBPPARG | |
| SCHEMBL10753671 | 0.78 | FFAR1 (0.60) | MMP12FFAR1FFAR4BCHEMAOB | |
| SCHEMBL28064100 | 0.77 | MMP12 (0.65) | MMP12FFAR1FFAR4BCHEMAOB | |
| SCHEMBL8887748 | 0.77 | MMP12 (0.65) | MMP12FFAR1FFAR4BCHEMAOB | |
| SCHEMBL28303067 | 0.75 | PPARG (0.76) | PPARG | |
| SCHEMBL28526468 | 0.75 | FFAR1 (0.57) | MMP12FFAR1FFAR4BCHEMAOB | |
| SCHEMBL3119335 | 0.75 | PTPN1 (0.49) | ACACBACACAMMP12FFAR1FFAR4 | |
| SCHEMBL5613493 | 0.75 | MMP12 (0.92) | MMP12FFAR1FFAR4BCHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2011-05-19 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| EP-1660449-B1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | disclosed |
| US-7528120-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2009-05-05 | — | — | US | disclosed |
| US-20060264403-A1 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2006-11-23 | — | — | US | disclosed |
| US-20060166940-A1 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1660449-A1 | AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| EP-1539674-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005021503-A1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004024673-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | ACACB 2215/4885ACACA 2257/4885MMP12 4810/4885 |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | ACACB 2215/4885ACACA 2257/4885MMP12 4810/4885 |
| US-20060166940-A1 | Amino-propanol derivatives | ADRB1, ADRB3, ADRA1D | ACACB 3014/4885ACACA 2324/4885MMP12 4848/4885 |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | ACACB 2215/4885ACACA 2257/4885MMP12 4810/4885 |
| US-20060264403-A1 | Aminopropanol derivatives | ADRB1, ADRA1D, ADRA1A | ACACB 2215/4885ACACA 2257/4885MMP12 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.